Modifying Antiretroviral Therapy in Virologically Suppressed HIV-Infected Patients
Summary
- STRIIVING study demonstrated that switching from virologically suppressive regimen (2 NRTIs plus PI, NNRTI, or INSTI) to single-tablet, once-daily abacavir/dolutegravir/lamivudine was noninferior to continuing baseline ART for maintenance of virologic suppression at Week 24[Trottier 2017]
- NEAT-022 study showed that switching virologically suppressed patients with high cardiovascular risk from their current regimen to dolutegravir-based ART was noninferior and improved lipid profiles[Gatell 2017; Gatell 2019]
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content
Keywords: Switch Strategies